Semaglutide
Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
Novo Nordisk · Phase 3 · Status n/r · Enrollment 480
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide: endpoint not reported